RxPONDER Trial and Immunotherapy
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
RxPONDER Trial and Immunotherapy
-
ナレーター：
-
著者：
このコンテンツについて
Drs Lidia Schapira and Kevin Kalinsky discuss the RxPONDER trial and immunotherapy.
Relevant disclosures can be found with the episode show notes on Medscape.com (https://www.medscape.com/viewarticle/963171). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US healthcare professionals.
21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer https://www.nejm.org/doi/10.1056/NEJMoa2108873
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6193457/
Randomized Comparisons of Adjuvant Aromatase Inhibitor Exemestane Plus Ovarian Function Suppression vs Tamoxifen in Premenopausal Women With Hormone Receptor–Positive Early Breast Cancer: Update of the TEXT and SOFT Trials https://www.abstractsonline.com/pp8/#!/10462/presentation/645
Breast Cancer Index https://www.breastcancerindex.com/
Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7768339/
Continuous Versus Intermittent Extended Adjuvant Letrozole for Breast Cancer: Final Results of Randomized Phase III SOLE (Study of Letrozole Extension) and SOLE Estrogen Substudy https://linkinghub.elsevier.com/retrieve/pii/S0923-7534(21)02492-3
Event-free Survival With Pembrolizumab in Early Triple-Negative Breast Cancer https://www.nejm.org/doi/10.1056/NEJMoa2112651